Recent Finacing
Recent Raise
Nkarta develops engineered allogeneic and CAR‑NK cell therapies using NK expansion and engineering technologies, advancing NKX101 (NKG2D) and CD19 CAR‑NK programs in IND‑enabling studies, clinical trials and GMP manufacturing.
